בליאומיצין PFI

Land: Israel

Sprache: Hebräisch

Quelle: Ministry of Health

Wirkstoff:

BLEOMYCIN SULFATE

Verfügbar ab:

MEGAPHARM LTD

ATC-Code:

L01DC01

Darreichungsform:

אבקה להכנת תמיסה לזריקה

Zusammensetzung:

BLEOMYCIN SULFATE 15000 IU/VIAL

Verabreichungsweg:

לתוך קרום הריאה, תוך-עורקי, תוך-ורידי, תת-עורי, תוך-שרירי, לתוך בקע

Verschreibungstyp:

מרשם נדרש

Hergestellt von:

BAXTER ONCOLOGY GmbH, GERMANY

Therapiegruppe:

BLEOMYCIN

Therapiebereich:

BLEOMYCIN

Anwendungsgebiete:

Bleomycin is useful in the management of the following neoplasms: Squamous cell carcinoma affecting the mouth, nasopharynx and paranasal sinuses, larynx, oesaphagus, cervix, vagina, penis and skin. Well differentiated tumors usually respond better than anaplastic ones.Hodgkin's disease and other malignant lymphomas, including mycosis fungoides. Testicular carcinoma (seminoma and no seminoma) .Malignant effusions of serous cavities (intrapleural and intraperitoneal).Secondary indications in which bleomycin has been shown to be of some value include metastatic malignant melanoma, carcinoma of the thyroid lung and bladder. Local treatment of refractory warts. Bleomycin can be used as a single agent, but is generally used in combination with other cytotoxics and/or with radiation therapy.

Berechtigungsdatum:

2020-09-30